<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131776</url>
  </required_header>
  <id_info>
    <org_study_id>NTEC-2021-0234</org_study_id>
    <nct_id>NCT05131776</nct_id>
  </id_info>
  <brief_title>EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.</brief_title>
  <official_title>Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outcomes of concurrent EUS-guided intra-tumour injection of P-32 microparticles (OncoSil;&#xD;
      OncoSil Medical, Australia) with chemotherapy in locally advanced pancreatic carcinoma in the&#xD;
      local population is uncertain.&#xD;
&#xD;
      The aim of the current study is to assess efficacy and safety of the intervention in the&#xD;
      local population. We hypothesis that the intervention is safe and useful for tumour&#xD;
      downstaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This would be a cohort study including patients with locally advanced pancreatic cancer&#xD;
      medically fit to receive chemotherapy. Eligible patients would receive gemcitabine (GNP; 28-&#xD;
      day cycles). P-32 microparticles (OncoSil; OncoSil Medical) implantation will be planned at&#xD;
      weeks 4-5. P-32 activity will be calculated from patients' tumor volume (TV) to deliver 100&#xD;
      Gy absorbed dose, with implantation assessment by EUS and Bremsstrahlung SPECT/CT imaging.&#xD;
      The primary endpoint was safety and tolerability, graded using CTCAE v4.0. Response will be&#xD;
      assessed using RECIST 1.1 with 8-weekly CT scans and FDG-PET scans at baseline and week 12.&#xD;
      The outcome parameters include adverse events, response of the tumour, local progression free&#xD;
      survival and overall survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>OncoSil™ is comprised of OncoSil Phosphorous-32 Microparticles (hereafter Microparticles) and OncoSil Diluent (hereafter Diluent). OncoSil™ is an active implantable (radiological) medical device intended for use in brachytherapy, where cancer is treated by the insertion of radioactive implants directly into the cancerous tissue. OncoSil™ has been designed to be injected directly into, and to deliver an average absorbed dose of 100 Gy to the target treatment tumour. In therapeutic use 98% of the radiation is delivered within 81 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 day</time_frame>
    <description>Any untoward medical occurrence, unintended disease or injury, oruntoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Disease Control Rate</measure>
    <time_frame>16 week</time_frame>
    <description>proportion of study participants whose local tumour response is stable disease (SD), partial response (PR), or complete response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>the time from enrolment to the date of the radiological scan used to determine local tumour progression or date of death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>the time from enrolment to the date of tumour progression or of recurrence (in case of complete response (CR))</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Endoscopic Ultrasound</condition>
  <arm_group>
    <arm_group_label>EUS-guided oncosil injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-guided oncosil injection</intervention_name>
    <description>All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.</description>
    <arm_group_label>EUS-guided oncosil injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Study participants are ≥ 18 years of age at screening.&#xD;
&#xD;
          2. Histologically or cytologically proven adenocarcinoma of the pancreas.&#xD;
&#xD;
          3. Unresectable locally advanced pancreatic carcinoma. Patients with technically&#xD;
             resectable tumours (T1-T3) will also be eligible, if they are deemed unresectable due&#xD;
             to medical comorbidities or refusal of surgery.&#xD;
&#xD;
          4. Pancreatic target tumour diameter ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest axis)&#xD;
&#xD;
          5. An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100.&#xD;
&#xD;
          6. Willing and able to complete study procedures within the study timelines.&#xD;
&#xD;
          7. Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
          8. Adequate liver function: Serum SGOT/AST and serum SGPT/SLT &lt; 3 times ULN and serum&#xD;
             bilirubin &lt;1.5 times the ULN unless the patient is known to have prior Gilbert's&#xD;
             Syndrome.&#xD;
&#xD;
          9. Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute&#xD;
             neutrophil count (ANC) ≥ 1,500/mm3, haemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm3.&#xD;
&#xD;
         10. Life expectancy of at least 3 months at the time of screening as judged by the&#xD;
             investigator.&#xD;
&#xD;
         11. Not pregnant, and if of childbearing potential, agrees to use adequate birth control&#xD;
             (hormonal or barrier method of birth control or abstinence) prior to study entry and&#xD;
             during the study and agrees not to donate sperm or ova, for the duration of the study&#xD;
             and 12 months post implantation of the investigational device.&#xD;
&#xD;
         12. Provide signed Informed Consent.&#xD;
&#xD;
         13. Technically feasible - tumour must be within reach of the EUS probe for fine needle&#xD;
             Injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than one primary lesion.&#xD;
&#xD;
          2. Any prior radiotherapy or chemotherapy for pancreatic cancer.&#xD;
&#xD;
          3. Use of other investigational agent at the time of screening, or within 30 days or five&#xD;
             half-lives of Screening Visit 1, whichever is longer.&#xD;
&#xD;
          4. History of malignancy, treated or untreated, within the past five years whether or not&#xD;
             there is evidence of local recurrence or metastases, with the exception of basal cell&#xD;
             carcinoma of the skin and cervical carcinoma in situ.&#xD;
&#xD;
          5. Evidence of tumour invasion into stomach, duodenum or peritoneum&#xD;
&#xD;
          6. In the opinion of the investigator, EUS directed implantation posing undue study&#xD;
             participant risk. This includes:&#xD;
&#xD;
               1. Where previous EUS-FNA was considered technically too difficult to perform;&#xD;
&#xD;
               2. Imaging demonstrates multiple collateral vessels surrounding or adjacent to the&#xD;
                  target tumour within the pancreas;&#xD;
&#xD;
               3. Presence (or significant risk) of varices near to the target tumour.&#xD;
&#xD;
          7. A known allergy or history of hypersensitivity to silicon, Phosphorus or any of the&#xD;
             OncoSil™ components.&#xD;
&#xD;
          8. Patients who do not consent to chemotherapy&#xD;
&#xD;
          9. Actively on medication that increase bleeding risk (i.e. aspirin, clopidogrel,&#xD;
             warfarin, NOAC).&#xD;
&#xD;
         10. Any other health condition that would preclude participation in the study in the&#xD;
             judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anthony YB Teoh, FRCSEd</last_name>
    <phone>35052956</phone>
    <email>anthonyteoh@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zero Chung</last_name>
    <phone>35052956</phone>
    <email>zerochung@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgery, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony YB Teoh, FRCSEd(Gen)</last_name>
      <phone>35052956</phone>
      <email>anthonyteoh@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Anthony YB Teoh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Rosemurgy A, Luzardo G, Cooper J, Bowers C, Zervos E, Bloomston M, Al-Saadi S, Carroll R, Chheda H, Carey L, Goldin S, Grundy S, Kudryk B, Zwiebel B, Black T, Briggs J, Chervenick P. 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. J Gastrointest Surg. 2008 Apr;12(4):682-8. doi: 10.1007/s11605-007-0430-6. Epub 2008 Feb 12.</citation>
    <PMID>18266048</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Anthony Teoh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Endoscopic ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

